Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEP-4199 CR for treatment of bipolar I depression
jRCT2031210559Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Dec 2021
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of SEP-4199 in bipolar I disorder (3 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Change from Baseline to Week 6 in MADRS total score. Started Dec 2021; status: completed.
02
Drugs
SEP-4199
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on jRCT2031210559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210559.